NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
Phase 1
Completed
- Conditions
- Adult Acute Eosinophilic LeukemiaAdult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAdult Pure Erythroid LeukemiaRecurrent Adult Acute Myeloid LeukemiaAdult Acute Megakaryoblastic LeukemiaAdult Acute Myelomonocytic LeukemiaRecurrent DiseaseAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With Minimal Differentiation
- Interventions
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00383474
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
Phase 2
Completed
- Conditions
- Pancreatic CancerAdenocarcinoma of the PancreasStage IV Pancreatic CancerStage II Pancreatic CancerRecurrent Pancreatic CancerStage III Pancreatic Cancer
- Interventions
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00383760
- Locations
- 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease
Completed
- Conditions
- Diabetes MellitusAtherosclerosisHyperlipidemiaHypertension
- First Posted Date
- 2006-09-29
- Last Posted Date
- 2017-10-06
- Target Recruit Count
- 216
- Registration Number
- NCT00382564
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
Phase 2
Completed
- Conditions
- Stage III Childhood Hodgkin LymphomaStage IV Childhood Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaChildhood Mixed Cellularity Hodgkin LymphomaChildhood Nodular Lymphocyte Predominant Hodgkin LymphomaRecurrent/Refractory Childhood Hodgkin LymphomaStage I Adult Hodgkin LymphomaStage I Childhood Hodgkin LymphomaAdult Lymphocyte Depletion Hodgkin LymphomaChildhood Nodular Sclerosis Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT00381940
- Locations
- 🇺🇸
Children's Oncology Group, Philadelphia, Pennsylvania, United States
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
Phase 2
Completed
- Conditions
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Eosinophilic LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChronic Myelomonocytic LeukemiaEssential ThrombocythemiaPhiladelphia Chromosome Negative Chronic Myelogenous LeukemiaPolycythemia VeraPrimary MyelofibrosisAccelerated Phase Chronic Myelogenous LeukemiaRelapsing Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00381550
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase 2
Completed
- Conditions
- Childhood Spinal Cord NeoplasmChildhood Cerebral Anaplastic AstrocytomaRecurrent Childhood Brain Stem GliomaChildhood OligodendrogliomaRecurrent Childhood EpendymomaRecurrent Childhood Medulloblastoma
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2017-11-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 97
- Registration Number
- NCT00381797
- Locations
- 🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
Phase 2
Completed
- Conditions
- Stage III Thyroid Gland Medullary Carcinoma AJCC v7Stage IV Thyroid Gland Papillary Carcinoma AJCC v7Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7Unresectable Thyroid Gland CarcinomaStage IV Thyroid Gland Medullary Carcinoma AJCC v7Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7Thyroid Gland Oncocytic CarcinomaDifferentiated Thyroid Gland CarcinomaStage III Thyroid Gland Follicular Carcinoma AJCC v7
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacogenomic Study
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT00381641
- Locations
- 🇺🇸
Illinois CancerCare-Peoria, Peoria, Illinois, United States
🇺🇸Southern Illinois University School of Medicine, Springfield, Illinois, United States
🇺🇸Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States
Improving Outcomes in Patients With Kidney Disease Due to Diabetes
Phase 2
Completed
- Conditions
- DiabetesKidney DiseaseHypertension
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2010-03-02
- Target Recruit Count
- 92
- Registration Number
- NCT00381134
- Locations
- 🇺🇸
The University of Texas Southwestern Medical Center, Dallas, Texas, United States
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
Phase 2
Completed
- Conditions
- Clear Cell Renal Cell CarcinomaRecurrent Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v7
- Interventions
- Biological: BevacizumabOther: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 361
- Registration Number
- NCT00378703
- Locations
- 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Grant Medical Center, Columbus, Ohio, United States
🇺🇸Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, United States
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
Phase 1
Completed
- Conditions
- Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Brain TumorAdult GliosarcomaRecurrent Adult Brain Tumor
- Interventions
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00379080
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States